Business Description
Scribe Therapeutics Inc
NAICS : 325414
SIC : 2836
Description
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.4 | |||||
Equity-to-Asset | -1.83 | |||||
Debt-to-Equity | -0.29 | |||||
Debt-to-EBITDA | -2.28 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y Total Revenue Growth Rate Estimate | -47.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.97 | |||||
Quick Ratio | 0.97 | |||||
Cash Ratio | 0.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -50.94 | |||||
Net Margin % | -42.62 | |||||
EBITDA Margin % | -35.45 | |||||
FCF Margin % | -90.84 | |||||
OCF Margin % | -88.35 | |||||
ROA % | -21.15 | |||||
ROIC % | -40.42 | |||||
ROC (Joel Greenblatt) % | -182.52 | |||||
ROCE % | -41.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.89 | |||||
EV-to-EBIT | -26.55 | |||||
EV-to-Forward-EBIT | -5.43 | |||||
EV-to-EBITDA | -31.05 | |||||
EV-to-Revenue | 11.01 | |||||
EV-to-Forward-Revenue | 84.24 | |||||
EV-to-FCF | -12.12 | |||||
Earnings Yield (Greenblatt) % | -3.77 | |||||
FCF Yield % | -8.26 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SCTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scribe Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 51.174 | ||
| EPS (TTM) ($) | -2.6 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 54.02 | ||
| 14-Day ATR ($) | 3.689909 | ||
| 20-Day SMA ($) | 29.26575 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 17.305 - 39.6 | ||
| Shares Outstanding (Mil) | 18.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scribe Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scribe Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Scribe Therapeutics Inc Frequently Asked Questions
What is Scribe Therapeutics Inc(SCTX)'s stock price today?
The current price of SCTX is $29.74. The 52 week high of SCTX is $39.60 and 52 week low is $17.31.
When is next earnings date of Scribe Therapeutics Inc(SCTX)?
The next earnings date of Scribe Therapeutics Inc(SCTX) is .
Does Scribe Therapeutics Inc(SCTX) pay dividends? If so, how much?
Scribe Therapeutics Inc(SCTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers